Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

MMJ Phytotech CEO will outline medicinal cannabis strategy at CEO Session

The company has this week entered into a cannabis concentrate program agreement with a Canadian company.
Cannabis and medicinal cannabis products
Jason Conroy will present at the CEO Session in Sydney on October 22

MMJ PhytoTech Ltd (ASX:MMJ) has an active strategy in the medicinal cannabis sector which chief executive officer Jason Conroy will outline at the Proactive CEO Sessions in Sydney on Monday, October 22.

The company recently confirmed the disposal of subsidiary PhytoTech Therapeutics Ltd (PTL) to Harvest One Cannabis Inc (TSX-V:HVT), which led to suspension from the ASX.

READ: MMJ PhytoTech applies for ASX re-quotation, Canadian cannabis investment enters distribution agreement

A re-quotation application has been made, which also incorporates a change of name to MMJ Group Holdings Limited.

This week the company has confirmed that its investment MediPharm Labs Inc (TSX-V:LABS) entered into a cannabis concentrate program agreement with Emerald Health Therapeutics Inc (TSX-V:EMH).

MMJ’s investment in MediPharm amounts to C$5 million, comprising 5.88 million shares at 85 Canadian cents per share and 2.94 million warrants exercisable at C$1.20 a share by October 2020.

This agreement enables Emerald to provide pharmaceutical-grade cannabis concentrate products produced by MediPharm to its large base of registered patients as well as premium concentrates for adult-use recreational consumers.

MediPharm is focused on downstream secondary extraction methodology, distillation and cannabinoid isolation and purification.

The company operates of one the largest cannabis concentrate manufacturing facilities in Canada and is built current good manufacturing practices and ISO standards.

Divestment notice lodged

Today MMJ announced that it has lodged a notice with the TSX Venture Exchange stating its intention to divest up to 5 million of its 53.333 million shares held in Harvest One.

The notice is a Canadian regulatory requirement as MMJ’s shareholding of approximately 30% in Harvest One is more than the 20% ownership threshold.

On completion of the sale of PTL, MMJ’s shareholding in Harvest One will increase by the equivalent of C$6.86 million divided by the 10-day volume weighted average price of Harvest One shares preceding settlement of that sale.

Conroy said, “After being fully-invested since the end of July, and with a significant shareholding in Harvest One that will increase on completion of the PTL sale, it is prudent to be ready and able to trim our ownership stake so we can participate in other cannabis sector investment opportunities as they arise.”

Register for the CEO Session today to find out more.

Sydney details, Monday, October 22, 2018

Also featuring will be Yandal Resources Limited (ASX:YRL), High Peak Royalties Ltd (ASX:HPR), Minotaur Exploration Ltd (ASX:MEP) and The Hydroponics Company Ltd (ASX:THC).

Join our Crypto, Blockchain and Cannabis Telegram group here
View full MMJ profile View Profile

MMJ PhytoTech Ltd Timeline

Related Articles

1539364967_Cannabis-plant.jpg
October 10 2018
Management behind ICC International Cannabis Corp has a clear buy, build and sell strategy
cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use